Antonius M. Ter Laak
Pharmaceuticals R&D
Berlin, BE 13342, Germany
Berlin, BE 13342, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
KAT6A-inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches.
Journal: Acta crystallographica. Section D, Structural biology
Published: August 27, 2026
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor.
Journal: Journal of medicinal chemistry
Published: October 25, 2024
Best of both worlds: An expansion of the state of the art pKa model with data from three industrial partners.
Journal: Molecular informatics
Published: April 25, 2024
Large-scale evaluation of k-fold cross-validation ensembles for uncertainty estimation.
Journal: Journal of cheminformatics
Published: September 03, 2022
Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: November 03, 2021
Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.
Journal: Journal of medicinal chemistry
Published: October 26, 2021
Bayer's in silico ADMET platform: a journey of machine learning over the past two decades.
Journal: Drug discovery today
Published: March 30, 2020
Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.
Journal: Cancers
Published: December 12, 2019
Modeling Physico-Chemical ADMET Endpoints with Multitask Graph Convolutional Networks.
Journal: Molecules (Basel, Switzerland)
Published: December 01, 2019
Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile.
Journal: Journal of medicinal chemistry
Published: November 21, 2019
Discovery and optimization of pyridyl-cycloalkyl-carboxylic acids as inhibitors of microsomal prostaglandin E synthase-1 for the treatment of endometriosis.
Journal: Bioorganic & medicinal chemistry letters
Published: May 02, 2019
Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis.
Journal: Journal of medicinal chemistry
Published: February 02, 2019
Last Updated: 09/26/2026